Article thumbnail

Genetic studies in Alzheimer's disease

By Ya-Ping Tang and Elliot S. Gershon


Alzheimer's disease (AD), the most common cause of dementia in aged populations, is believed to be caused by both environmental factors and genetic variations. Extensive linkage and association studies have established that a broad range of loci are associated with AD, including both causative and susceptibility (risk factor) genes. So far, at least three genes, APP, PS1, and PS2, have been identified as causative genes. Mutations in these genes have been found to cause mainly early-onset AD. On the other hand, APOE has been identified to be the most common high genetic risk factor for late-onset AD. Polymorphisms in the coding region, intron, and promoter region of certain genes constitute another kind of genetic variation associated with AD. A number of other genes or loci have been reported to have linkage with AD, but many show only a weak linkage or the results are not well reproduced. Currently, the measurable genetic associations account for about 50% of the population risk for AD. It is believed that more new loci will be found to associate with AD, either as causative genes or genetic risk factors, and that eventually the understanding of genetic factors in the pathogenesis of AD will be important for our efforts to cure this illness

Topics: Basic Research
Publisher: Les Laboratoires Servier
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. (1999). A full genome scan for late-onset Alzheimer’s disease. Hum Mol Genet.
  2. (1998). A genome survey for novel Alzheimer disease risk loci: results at 10-cM resolution.
  3. (1995). A mutation in Alzheimer’s disease destroying a splice acceptor site in the presenilin-1 gene.
  4. (1991). A mutation in the amyloid precursor protein associated with hereditary Alzheimer’s disease.
  5. (1997). A new pathogenic mutation in the APP gene (I716V) increases the relative proportion of Aβ42(43). Hum Mol Genet.
  6. A pathogenic mutation for probable Alzheimer’s disease in the APP gene at the N-terminus of β-amyloid.
  7. A portrait of Alzheimer secretases—new features and familiar faces.
  8. A presenilin-1-dependent γ-secretase-like protease mediates release of Notch intracellular domain.
  9. A role for presenilin-1 in nuclear accumulation of Ire1 fragments and induction of the mammalian unfolded protein response.
  10. A second locus for very-late-onset Alzheimer disease: a genome scan reveals linkage to 20p and epistasis between 20p and the amyloid precursor protein region.
  11. (1995). A yeast artificial chromosome contig from human chromosome 14q24 spanning the Alzheimer’s disease locus AD3. Hum Mol Genet.
  12. (1998). A-2 macroglobulin is genetically associated with Alzheimer disease. Nat Genet.
  13. Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology.
  14. (1997). Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins.
  15. (1987). Acetylcholinesterase fibers and the development of senile plaques. Brain Res.
  16. Aging and the occurrence of dementia: findings from a population-based cohort with a large sample of nonagenarians.
  17. Allelic association between the D10S1423 marker and Alzheimer’s disease in a German population.
  18. (1996). Allelic association but only weak evidence for linkage to the apolipoprotien E locus in late-onset Swedish Alzheimer families.
  19. (1993). Alzheimer disease and the prion disorders amyloid β–protein and prion protein amyloidoses.
  20. Alzheimer disease.
  21. (1996). Alzheimer-associated presenilins 1 and 2: neuronal expression in brain and localization to intracellular membranes in mammalian cells. Nat Med.
  22. Alzheimer’s dementia and Down’s syndrome. Genetic evidence suggesting an association.
  23. (1994). Alzheimer’s disease and possible gene interaction.
  24. Alzheimer’s disease and the amyloid cascade hypothesis: 10 years on.
  25. (1996). Alzheimer’s disease associated with mutations in presenilin 2 is rare and variably penetrant. Hum Mol Genet.
  26. Alzheimer’s disease: genes, pathogenesis and risk prediction.
  27. (2001). Alzheimer’s disease: genes, proteins, and therapy. Physiol Rev.
  28. Alzheimer’s disease: perspectives for the new millennium.
  29. (1992). Alzheimer’s disease: the amyloid cascade hypothesis.
  30. Amyloid β-peptide is produced by cultured cells during normal metabolism.
  31. Amyloid β–protein precursor: new clues to the genesis of Alzheimer’s disease.
  32. (1997). Amyotrophic lateral sclerosis and Alzheimer disease. Lessons from model systems. Rev Neurol
  33. An accomplice for γ-secretase brought into focus.
  34. (1998). An Alzheimer’s disease-linked PS1 variant rescues the developmental abnormalities of PS1-deficient embryos.
  35. (1994). An increased percentage of long amyloid β protein secreted by familial amyloid β protein precursor (β APP717) mutants.
  36. An α-2-macroglobulin insertion-deletion polymorphism in Alzheimer disease.
  37. (1996). and PS2) in human and murine tissues.
  38. (1998). Apo E and Apo CI loci are associated with dementia in younger but not older late-onset cases. Dement Geriatr Cogn Disord.
  39. (1995). ApoE genotype and familial Alzheimer’s disease: a possible influence on age of onset in APP717 Val--> Ile mutated families. Neurosci Lett.
  40. ApoE genotype and survival from intracerebral haemorrhage.
  41. (1994). ApoE is a major susceptibility gene for Alzheimer’s disease. Curr Opin Biotechnol.
  42. (1995). ApoE3 binding to tau tandem repeat I is abolished by tau serine262 phosphorylation. Neurosci Lett.
  43. (1995). Apolipoprotein E and Alzheimer’s disease: ethnic variation in genotypic risks. Ann Neurol.
  44. (1996). Apolipoprotein E genotype: utility in clinical practice in Alzheimer’s disease.
  45. (1995). Apolipoprotein E genotypes and Alzheimer’s disease in a community study of elderly African-Americans. Ann Neurol.
  46. Apolipoprotein E in sporadic Alzheimer’s disease: allelic variation and receptor interactions.
  47. (1999). Apolipoprotein E promoter and α2-macroglobulin polymorphisms are not genetically associated with Chinese late-onset Alzheimer’s disease. Neurosci Lett.
  48. (1999). Apolipoprotein E promoter polymorphism and sporadic Alzheimer’s disease in a Japanese population. Neurosci Lett.
  49. Apolipoprotein E variation at the sequence haplotype level: implications for the origin and maintenance of a major human polymorphism.
  50. (1993). Apolipoprotein E: highavidity binding to β-amyloid and increased frequency of type 4 allele in lateonset familial Alzheimer disease.
  51. (1994). Apolipoprotein E4 allele in a population-based study of early-onset Alzheimer’s disease. Nat Genet.
  52. (1999). Association between Alzheimer’s disease and the NOS3 gene. Ann Neurol.
  53. (1999). Association between an α(2) macroglobulin DNA polymorphism and late-onset Alzheimer’s disease. Biochem Biophys Res Commun.
  54. (2002). Association between presenilin-1 Glu318Gly mutation and familial Alzheimer’s disease in the Australian population. Mol Psychiatry.
  55. Association of early-onset Alzheimer’s disease with an interleukin-1α gene polymorphism.
  56. Association of interleukin-1 gene polymorphisms with Alzheimer’s disease.
  57. (1997). Association of transferrin C2 allele with late-onset Alzheimer’s disease. Hum Genet.
  58. Aβ and Alzheimer’s disease: where do the presenilins fit in?
  59. (1996). Aβ-peptide length and apolipoprotein E genotype in Alzheimer’s disease. Ann Neurol.
  60. Candidate gene association studies in sporadic Alzheimer’s disease. Dement Geriatr Cogn Disord.
  61. (1995). Candidate gene for the chromosome 1 familial Alzheimer’s disease locus.
  62. Carboxyl-terminal fragments of Alzheimer β-amyloid precursor protein accumulate in restricted and unpredicted intracellular compartments in presenilin 1–deficient cells.
  63. (1987). Characterization and chromosomal localization of a cDNA encoding brain amyloid of Alzheimer’s disease.
  64. Complete genomic screen in late-onset familial Alzheimer disease. Evidence for a new locus on chromosome 12.
  65. (1998). Complete genomic screen in late-onset familial Alzheimer’s disease. Neurobiol Aging.
  66. Conservation of brain amyloid proteins in aged mammals and humans with Alzheimer’s disease.
  67. Contribution of APOE promoter polymorphisms to Alzheimer’s disease risk.
  68. (1997). Cyclooxygenase 2 RNA message abundance, stability, and hypervariability in sporadic Alzheimer neocortex.
  69. Cyclooxygenase-2 expression is increased in frontal cortex of Alzheimer’s disease brain.
  70. (1998). Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein.
  71. Deficient neurogenesis in forebrainspecific presenilin-1 knockout mice is associated with reduced clearance of hippocampal memory traces.
  72. Dementia: when is it not Alzheimer disease?
  73. (1991). Early-onset Alzheimer’s disease caused by mutations at codon 717 of the β-amyloid precursor protein gene.
  74. (1997). Education and other measures of socioeconomic status and risk of incident Alzheimer disease in a defined population of older persons. Arch Neurol.
  75. Effect of APOE genotype and promoter polymorphism on risk of Alzheimer’s disease.
  76. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium.
  77. (1998). Effects of PS1 deficiency on membrane protein trafficking in neurons.
  78. (1996). Endoproteolysis of presenilin 1 and accumulation of processed derivatives in vivo.
  79. Epidemiology of clinically diagnosed Alzheimer’s disease.
  80. (1996). Epidemiology of the dementias: recent developments and new approaches. Neurol Neurosurg Psychiatry.
  81. (1995). Epistatic effect of APP717 mutation and apolipoprotein E genotype in familial Alzheimer’s disease. Ann Neurol.
  82. (1998). Estimation of the genetic contribution of presenilin-1 and -2 mutations in a population-based study of presenile Alzheimer disease. Hum Mol Genet.
  83. Evidence for genetic linkage of Alzheimer’s disease to chromosome 10q.
  84. (1997). Evidence for phosphorylation and oligomeric assembly of presenilin 1.
  85. (1994). Excessive production of amyloid β-protein by peripheral cells of symptomatic and presymptomatic patients carrying the Swedish familial Alzheimer disease mutation.
  86. (2003). Exploring the etiology of Alzheimer disease using molecular genetics.
  87. (2000). FAD mutations in presenilin1 or amyloid precursor protein decrease the efficacy of a γ-secretase inhibitor: evidence for direct involvement of PS1 in the γ-secretase cleavage complex. Neurobiol Dis.
  88. (1991). Familial aggregation of Alzheimer’s disease and related disorders: a collaborative re-analysis of casecontrol studies.
  89. (1995). Familial Alzheimer’s disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer’s disease type 3 gene.
  90. Familial Alzheimer’s disease–inked presenilin 1 variants elevate Aβ1-42/1-40 ratio in vitro and in vivo.
  91. (1991). Frequency and distribution of Alzheimer’s disease in Europe: a collaborative study of 1980–1990 prevalence findings. The EURODEM-Prevalence Research Group. Ann Neurol.
  92. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late-onset families.
  93. Genetic and environmental factors in Alzheimer’s disease. Rev Neurol (Paris). 1999;155(suppl 4):S10-S16.
  94. (1997). Genetic association of the low-density lipoprotein receptor–related protein gene (LRP), an apolipoprotein E receptor, with late-onset Alzheimer’s disease.
  95. (1999). Genetic association of α2-macroglobulin with Alzheimer’s disease in a Finnish elderly population. Ann Neurol.
  96. Genetic epidemiology of Alzheimer’s disease.
  97. (1992). Genetic evidence for a novel familial Alzheimer’s disease locus on chromosome 14. Nat Genet.
  98. (1992). Genetic linkage evidence for a familial Alzheimer’s disease locus on chromosome 14.
  99. Genetic risk of Alzheimer’s disease: advising relatives.
  100. Goate AM. The genetics of late-onset Alzheimer’s disease.
  101. (1995). Head injury, amyloid β and Alzheimer’s disease. Nat Med.
  102. High expression of apolipoprotein E mRNA in the brains with sporadic Alzheimer’s disease. Dement Geriatr Cogn Disord.
  103. High tissue content of soluble β-1-40 I linked to cerebral amyloid angiopathy.
  104. (1997). Hyperaccumulation of FAD-linked presenilin 1 variants in vivo. Nat Med.
  105. Identification of novel genes in late-onset Alzheimer’s disease. Exp Gerontol.
  106. Immunization with amyloid-β attenuates Alzheimer-disease–like pathology in the PDAPP mouse.
  107. (1996). In situ hybridization analysis of presenilin 1 mRNA in Alzheimer disease and in lesioned rat brain.
  108. (1993). Increased amyloid β-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease.
  109. (1996). Increased amyloid-β42(43) in brains of mice expressing mutant presenilin 1.
  110. (1999). Increased expression of cyclooxygenases and peroxisome proliferator-activated receptor–γ in Alzheimer’s disease brains. Biochem Biophys Res Commun.
  111. (1994). Isoform-specific interactions of apolipoprotein E with microtubule-associated protein tau: implications for Alzheimer disease.
  112. (1995). LDL receptor–related protein, a multifunctional ApoE receptor, binds secreted β-amyloid precursor protein and mediates its degradation.
  113. Linkage of plasma Aβ42 to a quantitative locus on chromosome 10 in late-onset Alzheimer’s disease pedigrees.
  114. Linkage studies in familial Alzheimer disease: evidence for chromosome 19 linkage.
  115. (1998). Localization and possible functions of presenilins in brain. Rev Neurosci.
  116. (1992). Mapping of a gene predisposing to early-onset Alzheimer’s disease to chromosome 14q24.3. Nat Genet.
  117. Maturation and endosomal targeting of β-site amyloid precursor protein–cleaving enzyme. The Alzheimer’s disease β-secretase.
  118. (1986). Microtubule-associated protein tau (tau) is a major antigenic component of paired helical filaments in Alzheimer disease.
  119. (1991). Mis-sense mutation Val----Ile in exon 17 of amyloid precursor protein gene in Japanese familial Alzheimer’s disease.
  120. (2002). Modification of brain aging and neurodegenerative disorders by genes, diet, and behavior. Physiol Rev.
  121. Molecular and prospective phenotypic characterization of a pedigree with familial Alzheimer’s disease and a missense mutation in codon 717 of the β-amyloid precursor protein gene.
  122. Molecular genetics of Alzheimer’s disease.
  123. (1998). Mutant genes in familial Alzheimer’s disease and transgenic models. Annu Rev Neurosci.
  124. (1997). Mutant presenilins of Alzheimer’s disease increase production of 42-residue amyloid β-protein in both transfected cells and transgenic mice. Nat Med.
  125. (1990). Mutation of the Alzheimer’s disease amyloid gene in hereditary cerebral hemorrhage, Dutch type.
  126. (1994). Mutations associated with a locus for familial Alzheimer’s disease result in alternative processing of amyloid β–protein precursor.
  127. (1995). Mutations of the presenilin I gene in families with early-onset Alzheimer’s disease. Hum Mol Genet.
  128. (1995). Neurodegeneration in the central nervous system of apoE-deficient mice. Exp Neurol.
  129. (1986). Neurofibrillary tangles of Alzheimer disease share antigenic determinants with the axonal microtubule–associated protein tau (tau).
  130. (1999). Neuropathology of Alzheimer’s disease: what is new since A. Alzheimer? Eur Arch Psychiatry Clin Neurosci.
  131. Neurotrophic and neurotoxic effects of amyloid β protein: reversal by tachykinin neuropeptides.
  132. Novel precursor of Alzheimer’s disease amyloid protein shows protease inhibitory activity.
  133. Photoactivated γ-secretase inhibitors directed to the active site covalently label presenilin 1.
  134. (2000). Piecing together Alzheimer’s. Sci Am.
  135. (1995). Polarized sorting of β-amyloid precursor protein and its proteolytic products in MDCK cells is regulated by two independent signals.
  136. Potential of transcriptional coordination of nice genes associated with Alzheimer’s disease. Alzheimer’s Rep.
  137. (1995). Predictors of cognitive decline after cardiac operation. Ann Thorac Surg.
  138. (1992). Presenile dementia and cerebral haemorrhage linked to a mutation at codon 692 of the β-amyloid precursor protein gene. Nat Genet.
  139. Presenilin 1 facilitates the constitutive turnover of β-catenin: differential activity of Alzheimer’s disease–linked PS1 mutants in the β-catenin–signaling pathway.
  140. Presenilin function in APP processing.
  141. Presenilin-1 mutations downregulate the signalling pathway of the unfolded-protein response.
  142. Presenilins and early-onset familial Alzheimer’s disease.
  143. Presenilins are required for γ-secretase cleavage of β-APP and transmembrane cleavage of Notch-1.
  144. (1999). Presenilins: molecular switches between proteolysis and signal transduction. Trends Neurosci.
  145. Prevalence of Alzheimer’s disease in a community population of older persons. Higher than previously reported.
  146. (1992). Production of the Alzheimer amyloid β protein by normal proteolytic processing.
  147. Projections of Alzheimer’s disease in the United States and the public health impact of delaying disease onset.
  148. (1998). Pronounced impact of Th1/E47cs mutation compared with -491 AT mutation on neural APOE gene expression and risk of developing Alzheimer’s disease. Hum Mol Genet.
  149. Proteolytic release and nuclear translocation of Notch-1 are induced by presenilin-1 and impaired by pathogenic presenilin-1 mutations.
  150. Rapid Notch1 nuclear translocation after ligand binding depends on presenilin-associated γ-secretase activity.
  151. (1996). Recent advances in the genetics of Alzheimer’s disease and vascular dementia with an emphasis on gene–environment interactions.
  152. (1995). Relationship between plaques, tangles, and dystrophic processes in Alzheimer’s disease. Neurobiol Aging.
  153. (1996). Relative RNA message abundance in control and Alzheimer’s disease–affected human neocortex. Res Adv Alzheimer Dis Related Disord.
  154. (1993). Release of excess amyloid β protein from a mutant amyloid β protein precursor.
  155. (1993). Risk factors for lateonset Alzheimer’s disease: a population-based, case-control study. Ann Neurol.
  156. (1998). Risk for Alzheimer’s disease correlates with transcriptional activity of the APOE gene. Hum Mol Genet.
  157. (1996). Secreted amyloid β-protein similar to that in the senile plaques of Alzheimer’s disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer’s disease. Nat Med.
  158. (1991). Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer’s disease.
  159. SNP association studies in Alzheimer’s disease highlight problems for complex disease analysis. Trends Genet.
  160. (1998). Splicing mutation of presenilin-1 gene for early-onset familial Alzheimer’s disease. Hum Mutat.
  161. (1997). subcellular localization, and membrane orientation of the Alzheimer’s diseaseassociated presenilins.
  162. Susceptibility locus for Alzheimer’s disease on chromosome 10.
  163. Synergistic effects of traumatic head injury and apolipoprotein-ε4 in patients with Alzheimer’s disease.
  164. The -491 A/T polymorphism in the regulatory region of the apolipoprotein E gene and early-onset Alzheimer’s disease. Neurosci Lett. 1998;258:65-68.Basic research 26
  165. The -491AA polymorphism in the APOE gene is associated with increased plasma apoE levels in Alzheimer’s disease.
  166. The Alzheimer’s Disease Collaborative Group. Genetic association between intronic polymorphism in presenilin-1 gene and late-onset Alzheimer’s disease.
  167. (1996). The Alzheimer’s disease–associated presenilins are differentially phosphorylated proteins located predominantly within the endoplasmic reticulum. Mol Med.
  168. The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics.
  169. The amyloid precursor protein locus and very-late-onset Alzheimer disease.
  170. The amyloid protein gene is not duplicated in brains from patients with Alzheimer’s disease.
  171. (1998). The APOE-ε4 allele and the risk of Alzheimer disease among African-Americans, whites, and Hispanics.
  172. The deletion polymorphism and
  173. (1996). The gene defects responsible for familial Alzheimer’s disease. Neurobiol Dis.
  174. (1997). The genetic defect causing Huntington's disease: repeated in other contexts? Mol Med.
  175. (1995). The inhibitory effect of apolipoprotein E4 on neurite outgrowth is associated with microtubule depolymerization.
  176. The neuropathology of Alzheimer’s disease. In:
  177. The pathogenesis of Alzheimer’s disease. Is amyloid β-protein the beginning or the end?
  178. The precursor of Alzheimer’s disease amyloid A4 protein resembles a cell-surface receptor.
  179. (1998). The proteolytic fragments of the Alzheimer’s disease–associated presenilin-1 form heterodimers and occur as a 100–150-kDa molecular mass complex.
  180. The α2-macroglobulin gene in AD: a population-based study and meta-analysis.
  181. Toxic proteins in neurodegenerative disease.
  182. (1997). Transcriptional regulation of the mouse presenilin-1 gene.
  183. Two novel (M233T and R278T) presenilin-1 mutations in early-onset Alzheimer’s disease pedigrees and preliminary evidence for association of presenilin-1 mutations with a novel phenotype.
  184. Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and γ-secretase activity.
  185. Two-octapeptide repeat deletion of prion protein associated with rapidly progressive dementia.
  186. (1907). Uber eine eigenartige Erkrankung der Hirnrinde. Allg Z Psychiatr.
  187. White CL 3rd. Neuronal pathology in the nucleus basalis and associated cell groups in senile dementia of the Alzheimer’s type: possible role in cell loss.
  188. (1996). Wide range in age of onset for chromosome 1–related familial Alzheimer’s disease. Ann Neurol.
  189. (1996). Widespread neuronal expression of the presenilin-1 early-onset Alzheimer’s disease gene in the murine brain.
  190. α2-Macroglobulin and the risk of Alzheimer’s disease.
  191. α2-Macroglobulin gene and Alzheimer’s disease: confirmation of association by haplotypes analyses.
  192. (1992). α2-Macroglobulin, a multifunctional binding protein with targeting characteristics.
  193. (1994). β-Amyloid neurotoxicity requires fibril formation and is inhibited by congo red.
  194. (1999). β-Secretase cleavage of Alzheimer’s amyloid precursor protein by the transmembrane aspartic protease BACE.